Navigation Links
China Medical Technologies to Participate in Investor Events in November
Date:10/24/2007

BEIJING, Oct. 24 /Xinhua-PRNewswire-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in- vitro diagnostic products and high intensity focused ultrasound tumor therapy systems, today announced the following investor events:

Event Date Location

UBS China Life Sciences Conference November 8-9, 2007 Shanghai, China

2007

Goldman Sachs China Investment November 12-13, 2007 Beijing, China

Frontier Conference 2007

Credit Suisse Phoenix Health Care November 13-14, 2007 Phoenix, US

Conference

Credit Suisse China Healthcare November 15-23, 2007 New York, Boston,

Sector Global Roadshow London,

Hong Kong and

Singapore

China Medical Technologies' management team will discuss at these events the Company's strategies, operations and growth opportunities, as well as its published results to date with securities analysts and institutional investors.

Please contact UBS, Goldman Sachs and Credit Suisse for event details.

About China Medical Technologies, Inc.

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostics products using Enhanced Chemiluminescence (ECLIA) technology and Fluorescent in situ Hybridization (FISH) technology, to detect and monitor various diseases and disorders, and products using High Intensity Focused Ultra
'/>"/>

SOURCE China Medical Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. China tells officials not to hide SARS damage
2. China reports declining number of SARS Cases
3. China says patient may have SARS
4. 15 Anti-SARS Drugs Identified By China-Europe Team of Researchers
5. Adverse Effects Associated with Unauthorised Hepatitis A Vaccine in China
6. Pig Bacterium (Streptococcus suis) Kills 24 In China
7. Watch Out! Pollution hazard from E-waste recycling in India & China
8. French Fries In Cancer Controversy In China
9. China To Distribute Free Condoms To Combat AIDS/HIV
10. HIV Cases Steadily Increasing In China With The Toll Over 1.26 Lakh
11. India And China Discuss Import Of Encephalitis Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... it,s still too early to say that ... TUESDAY, Dec. 15 (HealthDay News) -- Common chemicals ... to the abnormal growth of breasts in boys, ... in a prominent medical journal for pediatricians, adds ... phthalates, whose safety has been questioned by some ...
(Date:12/15/2009)... when doctors decide benefits of imaging outweigh the risks ... can pose a serious risk to people with heart ... researchers exposed pacemakers to a simulated MRI magnetic field ... tip of the pacemaker lead, where it would touch ... to MRI magnetic pulses caused certain pacemakers to deliver ...
(Date:12/15/2009)... Accelify is proud to announce the addition ... David will serve as Director of Development in the ... Board of Advisors. ,, David Tokofsky was ... of Education in June 1995. As the Board Member ... 600,000 stretching from Northeast Los Angeles through East Los ...
(Date:12/15/2009)... and acquisitions are commonplace today. As competitors come ... a product portfolio they also must face integration ... A new free, white paper from Howard Leight ... Program: US Airways ," details how the merger ... newly formed company to enhance its occupational Hearing ...
(Date:12/15/2009)... -- Reportlinker.com announces that a new ... its catalogue: ,, The ... Market Forecasts to 2015, Competitive Benchmarking, ... ,, http://www.reportlinker.com/p0168100/The-Future-of-Autoimmune-Diseases-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html ,, ... has released its latest research "The ...
Breaking Medicine News(10 mins):Health News:Breast Growth in Boys Might Be Linked to Plastics Chemical 2Health News:Breast Growth in Boys Might Be Linked to Plastics Chemical 3Health News:Patients With Pacemakers Should Avoid MRI Scans 2Health News:Accelify Announces the Addition of David Tokofsky to its National Board of Advisors 2Health News:New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways 2Health News:New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways 3Health News:New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways 4Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 13Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 14Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 15Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 16Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 17Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 18Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 19Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 20Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 21Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 22Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 23
... the PSSIG for a Three-Year TermSAN FRANCISCO, Jan. 22 ... Rashidee, Quantros Director for Safety and Risk Management, has ... Interest Group (PSSIG). This international organization,s ongoing mission is ... applications for the exchange of key sets of clinical ...
... Travel Advantage Network , one of the nation,s fastest-growing ... G. Komen for the Cure , the global leader of ... sales and a Jeans Day, where employees purchase the opportunity ... raised $729 for Susan G. Komen for the Cure, the ...
... Jan. 22 McAuley Ministries, the new grant-making arm ... its first grant... and the recipient is the YMCA ... fund the construction of a green rooftop terrace for ... "The new Thelma Lovette YMCA touches several of McAuley ...
... announced today that,the physicians of Midwest Pulmonary and ... , The physicians are Susan ... Plumb, M.D. All are board-certified in pulmonology,and critical care ... the treatment of sleep disorders. , ...
... Hurricane Katrina, the health of survivors 65 and over ... of older adults not affected by the disaster, according ... Hopkins Bloomberg School of Public Health. The August 2005 ... hurricanes in U.S. history. Hurricane Katrina displaced thousands and ...
... longtime director of the HIV advocacy/education organization Project Inform, ... and Infectious Diseases (NIAID) Director,s Special Recognition Award for ... , Mr. Delaney in 1985 founded Project Inform, ... and advocacy organization based in San Francisco, and served ...
Other Medicine News:Health News:Quantros Director of Patient Safety and Risk Management is Elected Co-Chair of Patient Safety Special Interest Group (PSSIG) at HL7 2Health News:Quantros Director of Patient Safety and Risk Management is Elected Co-Chair of Patient Safety Special Interest Group (PSSIG) at HL7 3Health News:Grassroots Group Gets Travel Advantage Network Support 2Health News:YMCA of Greater Pittsburgh Receives $500,000 from McAuley Ministries for New Hill YMCA Roof 2Health News:YMCA of Greater Pittsburgh Receives $500,000 from McAuley Ministries for New Hill YMCA Roof 3Health News:Midwest Pulmonary and Critical Care Associates Will Join Aurora Medical Group 2Health News:Decline in health among older adults affected by Hurricane Katrina 2Health News:NIAID honors AIDS activist Martin Delaney 2
(Date:12/15/2009)... PARK, Calif., Dec. 15 SRI International, ... today the award of U.S. patent 7,592,021 for ... enhanced release of drugs through the human body,s ... drug delivery and allows for a much longer ... or liquids. ,, Transmucosal delivery is an effective ...
(Date:12/15/2009)... medical expert internationally recognized as a leading authority ... last month to suspend Doug Barron for doping ... the medical condition hypogonadism and was ... and discriminatory." ,, Hypogonadism is the ... referred to informally as Low T . ...
(Date:12/15/2009)... -- Fenwal Inc., a global medical technology company ... availability, announced today that the U.S. Food and ... InterSol ® platelet additive solution. Fenwal ... specialized product used in combination with human plasma ... used to prevent or treat bleeding. ,, InterSol ...
Breaking Medicine Technology:SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 2SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 3SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 4SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 5Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 2Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 3Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 4Fenwal Receives FDA Approval for New Solution Used to Store Donated Blood Platelets 2SearchAmerica 28R 29 President Daniel Johnson Named Ernst 26 Young Entrepreneur Of The Year 28R 29 50424 1SearchAmerica 28R 29 President Daniel Johnson Named Ernst 26 Young Entrepreneur Of The Year 28R 29 50424 2SearchAmerica 28R 29 President Daniel Johnson Named Ernst 26 Young Entrepreneur Of The Year 28R 29 50424 3Wisconsin Tobacco Tax Increase Is Positive Step for Health but Budget Disappoints by Cutting Funding for Tobacco Prevention Programs 50421 1Wisconsin Tobacco Tax Increase Is Positive Step for Health but Budget Disappoints by Cutting Funding for Tobacco Prevention Programs 50421 2Wisconsin Tobacco Tax Increase Is Positive Step for Health but Budget Disappoints by Cutting Funding for Tobacco Prevention Programs 50421 3Over One Thousand Blind Americans to March in Detroit 50418 1Over One Thousand Blind Americans to March in Detroit 50418 2
... Developed Through Joint Venture Between Bristol-Myers Squibb and ... of Its Kind in HIV Treatment -, PRINCETON, ... European Commission has granted marketing authorization for,ATRIPLA(R) (efavirenz 600 ... for commercialization in the,27 countries of the European Union, ...
... into Treatment Impact, Node-Positive ... Breast Cancer, Measuring ER/PR Scores, REDWOOD CITY, Calif., Dec. ... results from multiple studies,reinforcing the clinical utility of the company,s ... recurrence and the,likelihood of chemotherapy benefit for a large portion ...
Other Medicine Technology:European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 2European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 3European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 4European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 5European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 6European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 7European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 8European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 9Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R) 2Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R) 3Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R) 4Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R) 5Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R) 6Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R) 7
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 8.0 mm and length 8 mm....
... BacT/Alert 3D Signature is a state ... system that integrates blood, sterile body ... a powerful microbiology workstation with comprehensive ... volume identification and where expanded flexibility ...
... automated instrument that offers Rapid results (with ... same day turnaround), random or batch processing ... used for bacterial and yeast identification, antimicrobial ... a complete data management system. It processes ...
IDS Rapid One, a microbial identification system....
Medicine Products: